Search results

Hypertension and nephrology

SEPTEMBER 20, 2014

[Changes in prescribing practice of diuretics in the treatment of hypertension between 2007 and 2013 in the mirror of insurance data]

BARNA István, GYURCSÁNYI András

[Amongst diuretics, thiazides are the most commonly used antihypertensive agents. Due to their long-term effect, they are ideal for treatment of hypertension. Indapamide is a long-acting (half-life 14-16 hours) thiazide-like diuretic, which is effective in very small doses (1.25 to 5 mg). Indapamide mainly provides a forceful blood pressure lowering effect, by decreasing arteriolar and peripheral resistance due to its vasodilatative effect. Even in hypertensive, diabetic patients, indapamide does not affect the lipid metabolism or the carbohydrate metabolism. As an antihypertensive medicine, thiazide-type diuretics (only in small doses - 6.25- 12.5 mg hypothiazide, 12.5 mg chlorthalidone, 5 mg clopamide) can be the first choice, when dealing with essential hypertension disease without complications. They may also be used in monotherapy. When dealing with hypertension associated with old age or with isolated systolic hypertension, these products are recommended with “A” type evidence. For the treatment of left ventricular hypertrophy and post-stroke conditions associated with the treatment of hypertension, it is recommended to use indapamide in case of diabetes, furosemide and thiazide in case of a left ventricular dysfunction and heart failure, or a combination of these. When reviewing the national sales of mono-component diuretics between 2007 and 2013 in the National Health Insurance (OEP) database, we could see that the sales of hydrochlorothiazide, clopamide, and chlorthalidone decreased. In 2013 however, the sales of the latter experienced a turnover, which might indicate the activity of the followers of the new guideline. The use of diuretics with indapamide as their active substance increased. The prescription of diuretics used in a combination increased continuously between 2007 and 2010 and reached a monthly one million prescribed boxes. During the time in question, the use of products combined with hydrochlorothiazide (most products contain this agent) was the most dominant, but its share fell from 88% to 66% due to the growth of combinations containing the active ingredient indapamide. This is interesting because this combination is “unique” (perindopril + indapamide). During the period in question, only the prescription of this combination increased steadily. The use of diuretics is very important in antihypertensive therapy. If we compare the diuretics and their combinations to the recommendations, we can state that the treatment is done along the guidelines, or in other words the use of the metabolic neutral combination therapy is increasing.]

Hypertension and nephrology

MAY 20, 2012

[Too early publication? (priority of the Hungarian authors was saved by a South- American radiologist)]

RADÓ János

[It is supposed that the invention of diuretic (furosemide) renography was a premature discovery. This is suggested by the fact that it was rediscovered by more than one people. Author supported this contention by a statistical analysis of „citation intervals” performed on the basis of Garfield’s suggestions. The length of the time from the description of the procedure to the appearance of citations („citation interval”) proved to be an average of 21.3±9.6 (SD) years, significantly longer than in the case of the author’s five important other recognitions combined, where the average citation interval was 8.7±7.4 (SD) years (p<0.01). Camargo a South-American radiologist who first confirmed the original study, was later just in time the editor of a North American journal to save the priority of the original inventor Hungarian authors. In medical science the investigators take the risks in the interest of the patients including „publishing too early”.]

Hypertension and nephrology

SEPTEMBER 09, 2010

[Diuretikumok hypertoniában - 2010]

BARNA István

[Diuretics (especially thiazide derivatives and indapamide that also has vasodilator efficacy) are considered as first line treatment in hypertension. They are particularly favourable in the treatment of overweight, elderly, isolated systolic hypertensive patients suffering from type 2 diabetes and metabolic syndrome or in mild renal and cardiac insufficiency. They can be ideally combined with other antihypertensive agents (primarily with angiotensin-converting enzyme inhibitors, angiotensin receptor blocking agents és béta-blockers). If hypertension is associated with left ventricular hypertrophy or stroke indapamide is the appropriate choice. In case of left ventricular dysfunction and heart failure thiazide and/or furosemide is the adequate option. Low dose diuretics have no clinically relevant side effects and reduce cardiac mortality to the same extent as other pharmaceutical interventions.]

Hypertension and nephrology

FEBRUARY 28, 2011

[Combination of diuretics in resistant hypertension]

RADÓ János

[Resistant hypertension developed in a 60-year-old male patient with chronic renal insufficiency due to untreated high blood pressure for decades despite of the coadministration of furosemide, β-blocker, calcium channel blocker, angiotensin converting enzyme inhibitor and angiotensin receptor blocker. Breakthrough could be achieved by the combination of a tiazide compound and a loop diuretic (furosemide). It seemed to be worthwile publishing the case because the tiazide drug could be successfully administered below 30 ml/min GFR, where it is generally thought to be ineffective, and because both elements of the combination was given in very low doses relative to the kidney disease. The literature of the most important combinations of the tiazide preparations and the loop diuretics are reviewed and some historical aspects are given as well.]